Literature DB >> 20640954

"We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine.

Matthew J Mimiaga1, Steven A Safren, Sergiy Dvoryak, Sari L Reisner, Richard Needle, George Woody.   

Abstract

Ukraine has one of the most severe HIV/AIDS epidemics in Europe, with an estimated 1.63% of the population living with HIV/AIDS in 2007. Injection drug use (IDU) remains the predominant mode of transmission in Kiev - the capital and largest city. Prior reports suggest that the HIV infection rate among IDUs in Kiev reaches 33%, and many have poor and inequitable access to highly active antiretroviral therapy (HAART). Among those with access to HAART, little is understood about barriers and facilitators to HAART medication adherence. In May 2009, two semi-structured focus groups were conducted with HIV-infected IDUs seeking treatment at the City AIDS Center, Kiev. The goal was to use this information to adapt and tailor, to Ukrainian culture, an evidence-based intervention for improving adherence to HAART. All 16 participants attributed HIV infection to IDU. Their average age was 31.6 (SD=7.0), average time with HIV 5.7 years (SD=4.0), average time on HAART 2.5 years (SD=1.7), average time as IDU 14.6 years (SD=6.8), and 88% were on opioid substitution therapy. The most salient themes related to adherence barriers included: (1) harassment and discrimination by police; (2) opioid dependence; (3) complexity of drug regimen; (4) side effects; (5) forgetting; (6) co-occurring mental health problems; and (7) HIV stigma. Facilitators of adherence included: (1) cues for pill taking; (2) support and reminders from family, significant other, and friends; (3) opioid substitution therapy; and (4) wanting improved health. Additional factors explored included: (1) knowledge about HAART; (2) storage of medications; and (3) IDU and sexual risk behaviors. Findings highlighted structural and individual barriers to adherence. At the structural level, police discrimination and harassment was reported to be a major barrier to adherence to opioid substitution therapy and HAART. Privacy and stigma were barriers at the individual level. Recommendations for adherence interventions included education, training, and identification cards to show police that medication was for treatment of HIV, not for abuse; and involving family members and other systems of support for HIV treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640954      PMCID: PMC2952728          DOI: 10.1080/09540121003758515

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  16 in total

1.  Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.

Authors:  Martin C Donoghoe; Annemarie R Bollerup; Jeffrey V Lazarus; Stine Nielsen; Srdan Matic
Journal:  Int J Drug Policy       Date:  2007-06-21

Review 2.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

3.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring.

Authors:  S A Safren; M W Otto; J L Worth; E Salomon; W Johnson; K Mayer; S Boswell
Journal:  Behav Res Ther       Date:  2001-10

Review 4.  Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.

Authors:  Lynn E Sullivan; David S Metzger; Paul J Fudala; David A Fiellin
Journal:  Addiction       Date:  2005-02       Impact factor: 6.526

5.  Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study.

Authors:  N Kumarasamy; Steven A Safren; Sudha R Raminani; Robert Pickard; Romola James; A K Sri Krishnan; Suniti Solomon; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2005-08       Impact factor: 5.078

6.  Predictors of HIV sero-status among drug injectors at three Ukraine sites.

Authors:  Robert E Booth; Carol F Kwiatkowski; John T Brewster; Larisa Sinitsyna; Sergey Dvoryak
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

Review 7.  Substitution treatment of injecting opioid users for prevention of HIV infection.

Authors:  L Gowing; M Farrell; R Bornemann; L Sullivan; R Ali
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 8.  Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).

Authors:  Bruno Spire; Gregory M Lucas; M Patrizia Carrieri
Journal:  Int J Drug Policy       Date:  2007-01-26

Review 9.  Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview.

Authors:  France Lert; Michel D Kazatchkine
Journal:  Int J Drug Policy       Date:  2007-07-17

10.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Authors:  Perrine Roux; M Patrizia Carrieri; Virgine Villes; Pierre Dellamonica; Isabelle Poizot-Martin; Isabelle Ravaux; Bruno Spire
Journal:  Addiction       Date:  2008-09-04       Impact factor: 6.526

View more
  59 in total

1.  The HIV epidemic in Eastern Europe and Central Asia.

Authors:  Jack DeHovitz; Anneli Uuskula; Nabila El-Bassel
Journal:  Curr HIV/AIDS Rep       Date:  2014-06       Impact factor: 5.071

2.  Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan.

Authors:  Phillip L Marotta; Louisa Gilbert; Assel Terlikbayeva; Elwin Wu; Nabila El-Bassel
Journal:  Int J Drug Policy       Date:  2018-09-13

3.  Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.

Authors:  Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

4.  Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation.

Authors:  Anna Pecoraro; Matthew Mimiaga; Conall O'Cleirigh; Steven A Safren; Elena Blokhina; Elena Verbitskaya; Tatiana Yaroslavtseva; Andrey Ustinov; Dmitry A Lioznov; Edwin Zvartau; Evgeny Krupitsky; George E Woody
Journal:  AIDS Care       Date:  2014-09-29

5.  Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Iuliia Makarenko; Alyona Mazhnaya; Alexei Zelenev; Maxim Polonsky; Lynn Madden; Sergii Filippovych; Sergii Dvoriak; Sandra A Springer; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

Review 6.  HIV and the criminalisation of drug use among people who inject drugs: a systematic review.

Authors:  Kora DeBeck; Tessa Cheng; Julio S Montaner; Chris Beyrer; Richard Elliott; Susan Sherman; Evan Wood; Stefan Baral
Journal:  Lancet HIV       Date:  2017-05-14       Impact factor: 12.767

7.  Sovereign Rules and Rearrangements: Banning Methadone in Occupied Crimea.

Authors:  Jennifer J Carroll
Journal:  Med Anthropol       Date:  2018-11-27

8.  In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.

Authors:  Alyona Mazhnaya; Martha J Bojko; Ruthanne Marcus; Sergii Filippovych; Zahedsul Islam; Sergey Dvoriak; Frederick L Altice
Journal:  Drugs (Abingdon Engl)       Date:  2016-02-16

9.  Police confrontations among street-involved youth in a Canadian setting.

Authors:  Lianping Ti; Evan Wood; Kate Shannon; Cindy Feng; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2012-08-09

10.  Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine.

Authors:  Olga Morozova; Sergii Dvoryak; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.